MedTrace Logo

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

NCT05656027 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 469

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.

Conditions

  • Presbyopia
  • Refractive Error
  • Eye Diseases
  • Near Vision

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

LNZ101 (Aceclidine/Brimonidine) ophthalmic solution

DRUG

Aceclidine ophthalmic solution

LNZ100 Aceclidine ophthalmic solution

DRUG

Brimonidine

Brimonidine ophthalmic solution

Sponsors & Collaborators

  • LENZ Therapeutics, Inc

    lead OTHER

Principal Investigators

  • Kris Gambelin, BS · LENZ Therapeutics, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2023-12-15
Completion
2024-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656027 on ClinicalTrials.gov